PET/CT in diagnosis of movement disorders

Annals of the New York Academy of Sciences

Volumn 1228, Issue 1, 2011, Pages 93-108

  Berti, Valentina ^a   Pupi, Alberto ^a   Mosconi, Lisa ^b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Movement disorders; Parkinson's disease; PET CT

Indexed keywords

3 (2 FLUOROETHYL)SPIPERONE F 18; 4 AMINOBUTYRIC ACID RECEPTOR; BENZODIAZEPINE RECEPTOR; DESMETHOXYFALLYPRIDE F 18; DIHYDROTETRABENAZINE; DIHYDROTETRABENAZINE C 11; DIPRENORPHINE; DIPRENORPHINE C 11; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE F 18; DOPAMINE RECEPTOR STIMULATING AGENT; DOPAMINE TRANSPORTER; FLUMAZENIL C 11; FLUORODEOXYGLUCOSE F 18; FLUOROETHYLSPIPERONE F 18; GLUCOSE; LEVODOPA; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE; RACLOPRIDE C 11; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; VESICULAR MONOAMINE TRANSPORTER 2;

ALZHEIMER DISEASE; ARTICLE; ATAXIA; BASAL GANGLION; BRAIN ISCHEMIA; BRAIN METABOLISM; BRAIN STEM; CAUDATE NUCLEUS; CEREBRAL METABOLIC RATE OF GLUCOSE; CLINICAL PRACTICE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CORTICOBASAL DEGENERATION; CYCLOTRON; CYTOPLASM; DIAGNOSIS; DIAGNOSTIC VALUE; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; DOPAMINE METABOLISM; DOPAMINERGIC SYSTEM; DRUG UPTAKE; DYSTONIA; ESSENTIAL TREMOR; GENETIC DISORDER; HUMAN; HUNTINGTON CHOREA; HYPERMETABOLISM; IN VIVO STUDY; INFLAMMATION; KEARNS SAYRE SYNDROME; MEMORY DISORDER; MESENCEPHALON; MOLECULAR IMAGING; MOTOR CORTEX; MOTOR DYSFUNCTION; MYOCLONUS EPILEPSY; NERVE DEGENERATION; NERVOUS SYSTEM PARAMETERS; NEUROIMAGING; NEUROPATHY; NEUROTRANSMISSION; PARKINSON DISEASE; PREFRONTAL CORTEX; PROGRESSIVE SUPRANUCLEAR PALSY; PUTAMEN; RECEPTOR BINDING; RETINITIS PIGMENTOSA; SHY DRAGER SYNDROME; SPINOCEREBELLAR DEGENERATION; SYNAPSE; TEMPORAL CORTEX; TEMPORAL LOBE; TRAUMATIC BRAIN INJURY; TREATMENT RESPONSE; UPREGULATION;

EID: 79959786395     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2011.06025.x     Document Type: Article

References (100)

1. Tanner, C.M. & S.M. Goldman 1996. Epidemiology of Parkinson's disease. Neurol. Clin. 14: 317-335.
2. Wichmann, T. & M.R. DeLong 2003. Pathophysiology of Parkinson's disease: the MPTP primate model of the human disorder. Ann. N.Y. Acad. Sci. 991: 199-213.
3. Morrish, P.K., J.S. Rakshi, D.L. Bailey, et al 1998. Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [F-18] dopa PET. J. Neurol. Neurosurg. Psychiatry 64: 314-319.
4. Hughes, A.J., S.E. Daniel, L. Kilford & A.J. Lees 1992. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J. Neurol. Neurosurg. Psychiatry 55: 181-184.
5. Brooks, D.J., V. Ibanez, G.V. Sawle, et al 1990. Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive sopranuclear palsy. Ann. Neurol. 28: 547-555.
6. Bruck, A., A. Aalto, E. Nurmi, et al 2006. Striatal subregional 6-[18F]fluoro-L-dopa uptake in early Parkinson's disease: a two-year follow-up study. Mov. Disord. 21: 958-963.
7. Nurmi, E., H.M. Ruottinen, J. Bergman, et al 2001. Rate of progression in Parkinson's disease: a 6-[F-18]fluoro-l-dopa PET study. Mov. Disord. 16: 608-615.
8. Lee, C.S., A. Samii, V. Sossi, et al 2000. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann. Neurol. 47: 493-503.
9. Vander Borght, T.M., M.R. Kilbourn, R.A. Koeppe, et al 1995. In vivo imaging of the brain vesicular monoamine transporter. J. Nucl. Med. 36: 2252-2260.
10. Bohnen, N.I., R.L. Albin, R.A. Koeppe, et al 2006. Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson's disease. J. Cereb. Blood Flow Metab. 26: 1198-1212.
11. Frey, K.A., R.A. Koeppe, M.R. Kilbourn, et al 1996. Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging. Ann. Neurol. 40: 873-884.
12. Kazumata, K., V. Dhawan, T. Chaly, et al 1998. Dopamine transporter imaging with fluorine-18-FPCIT and PET. J. Nucl. Med. 39: 1521-1530.
13. Rinne, J.O., J. Bergman, H. Ruottinen, et al 1999. Striatal uptake of a novel PET ligand, [18F]beta-CFT, is reduced in early Parkinson's disease. Synapse 31: 119-124.
14. Innis, R.B., V.J. Cunningham, J. Delforge, et al 2007. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J. Cereb. Blood Flow Metab. 27:1533-1539.
15. Wang, J., C.T. Zuo, Y.P. Jiang, et al 2007. 18F-FP-CIT PET imaging and SPM analysis of dopamine transporters in Parkinson's disease in various Hoehn & Yahr stages. J. Neurol. 254: 185-190.
16. Nurmi, E., J. Bergman, O. Eskola, et al 2003. Progression of dopaminergic hypofunction in striatal subregions in Parkinson's disease using [18F]CFT PET. Synapse 48: 109-115.
17. Guttman, M., D. Stewart, D. Hussey, et al 2001. Influence of L-dopa and pramipexole on striatal dopamine transporter in early PD. Neurology 56: 1559-1564.
18. Rinne, U.K., A. Laihinen, J.O. Rinne, et al 1990. Positron emission tomography demonstrates dopamine D2 receptor supersensitivity in the striatum of patients with early Parkinson's disease. Mov. Disord. 5: 55-59.
19. Kaasinen, V., H.M. Ruottinen, K. Nagren, et al 2000. Upregulation of putaminal dopamine D2 receptors in early Parkinson's disease: a comparative PET study with [11C]raclopride and [11C]N-methylspiperone. J. Nucl. Med. 41: 65-70.
20. Van Royen, E., N.F. Verhoeff, J.D. Speelman, et al 1993. Multiple system atrophy ad progressive supranuclear palsy. Diminished striatal D2 receptor activity demonstrated by 123I-IBZM single photon emission computed tomography. Arch. Neurol. 50: 513-516.
21. Antonini, A., K.L. Leenders, P. Vontobel, et al 1997. Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease. Brain 120: 2187-2195.
22. Turjanski, N., A.J. Lees & D.J. Brooks 1997. In vivo studies on striatal dopamine D1 and D2 site binding in l-dopa-treated Parkinson's disease patients with and without dyskinesias. Neurology 49: 717-723.
23. Borghammer, P., M. Chakravarty, K.Y. Jonsdottir, et al 2010. Cortical hypometabolism and hypoperfusion in Parkinson's disease is extensive: probably even at early disease stages. Brain Struct. Funct. 214: 303-317.
24. Eidelberg, D., J.R. Moeller, V. Dhawan, et al 1994. The metabolic topography of parkinsonism. J. Cereb. Blood. Flow. Metab. 14: 783-801.
25. Eckert, T., A. Barnes, V. Dhawan, et al 2005. FDG PET in the differential diagnosis of parkinsonian disorders. Neuroimage 26: 912-921.
26. Bezard, E., A.R. Crossman, C.E. Gross & J.M. Brotchie 2001. Structures outside the basal ganglia may compensate for dopamine loss in the presymptomatic stages of Parkinson's disease. FASEB J. 15: 1092-1094.
27. Borghammer, P., P. Cumming, J. Aanerud, et al 2009. Subcortical elevation of metabolism in Parkinson's disease-a critical reappraisal in the context of global mean normalization. Neuroimage 47: 1514-1521.
28. Nagano-Saito, A., T. Kato, Y. Arahata, et al 2004. Cognitive- and motor-related regions in Parkinson's disease: FDOPA and FDG PET studies. Neuroimage 22: 553-561.
29. Alexander, G.E. & M.D. Crutcher 1990. Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci. 13: 266-271.
30. Berti, V., C. Polito, S. Ramat, et al 2010. Brain metabolic correlates of dopaminergic degeneration in de novo Parkinson's disease. Eur. J. Nucl. Med. Mol. Imaging 37: 537-544.
31. Moeller, J.R., T. Makamura, M.J. Mentis, et al 1999. Reproducibility of regional metabolic covariance patterns: comparison of four populations. J. Nucl. Med. 40: 1264-1269.
32. Asanuma, K., C. Tang, Y. Ma, et al 2006. Network modulation in the treatment of Parkinson's disease. Brain 129: 2667-2678.
33. Huang, C., P. Mattis, C. Tang, et al 2007. Metabolic brain networks associated with cognitive function in Parkinson's disease. Neuroimage 34: 714-723.
34. Kreutzberg, G.W. 1996. Microglia: a sensor for pathological events in the CNS. Trends Neurosci. 19: 312-318.
35. Ouchi, Y., S. Yagi, M. Yokokura & M. Sakamoto 2009. Neuroinflammation in the living brain of Parkinson's disease. Parkinsonism Relat. Disord. 15(Suppl 3): S200-S204.
36. Ouchi, Y., E. Yoshikawa, Y. Sekine, et al 2005. Microglial activation and dopamine terminal loss in early Parkinson's disease. Ann. Neurol. 57: 168-175.
37. Gerhard, A., N. Pavese, G. Hotton, et al 2006. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiol. Dis. 21: 404-412.
38. Jankovic, J. 2002. Essential tremor: a heterogenous disorder. Mov. Disord. 17: 683-644.
39. Parkinson Study Group. 2000. A multicenter assessment of dopamine transporter imaging with DOPASCAN/SPECT in parkinsonism. Neurology 55: 1540-1547.
40. Benamer, T.S., J. Patterson, D.G. Grosset, et al 2000. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]FP-CIT SPECT imaging: the [123I]FP-CIT study group. Mov. Disord. 15: 503-510.
41. Brooks, D.J., E.D. Playford, V. Ibanez, et al 1992. Isolated tremor and disruption of the nigrostriatal dopaminergic system: an 18F-dopa PET study. Neurology 42: 1554-1560.
42. Christine, C.W. & M.J. Aminoff 2004. Clinical differentiation of parkinsonian syndromes: prognostic and therapeutic relevance. Am. J. Med. 117: 412-419.
43. Stefanova, N., P. Bücke, S. Duerr & G.K. Wenning 2009. Multiple system atrophy: an update. Lancet Neurol. 8: 1172-1178.
44. Burn, D.J., G.V. Sawle & D.J. Brooks 1994. Differential diagnosis of Parkinson's disease, multiple system atrophy, and Steele-Richardson-Olszewski syndrome: discriminant analysis of striatal 18F-dopa PET data. J. Neurol. Neurosurg. Psychiatry. 57: 278-284.
45. Ghaemi, M., R. Hilker, J. Rudolf, et al 2002. Differentiating multiple system atrophy from Parkinson's disease: contribution of striatal and midbrain MRI volumetry and multi-tracer PET imaging. J. Neurol. Neurosurg. Psychiatry. 73: 517-523.
46. Gilman, S., K.A. Frey, R.A. Koeppe, et al 1996. Decreased striatal monoaminergic terminals in olivopontocerebellar atrophy and multiple system atrophy demonstrated with positron emission tomography. Ann. Neurol. 40: 885-892.
47. Gilman, S., R.A. Koeppe, L. Junck, et al 1999. Decreased striatal monoaminergic terminals in multiple system atrophy detected with positron emission tomography. Ann. Neurol. 45: 769-777.
48. Brooks, D.J., V. Ibanez, G.V. Sawle, et al 1992. Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with [11C] raclopride and positron emission tomography. Ann. Neurol. 31: 184-192.
49. Schreckenberger, M., S. Hagele, T. Siessmeier, et al 2004. The dopamine D2 receptor ligand 18F-desmethoxyfallypride: an appropriate fluorinated PET tracer for the differential diagnosis of parkinsonism. Eur. J. Nucl. Med. Mol. Imaging 31: 1128-1135.
50. Eidelberg, D., S. Takikawa, J.R. Moeller, et al Striatal hypometabolism distinguishing striatonigral degeneration from Parkinson's disease. Ann. Neurol. 33: 518-527.
51. Otsuka, M., Y. Ichiya, Y. Kuwabara, et al 1996. Glucose metabolism in the cortical and subcortical brain structures in multiple system atrophy and Parkinson's disease: a positron emission tomographic study. J. Neurol. Sci. 144: 77-83.
52. Taniwaki, T., M. Nakagawa, T. Yamada, et al 2002. Cerebral metabolic changes in early multiple system atrophy: a PET study. J. Neurol. Sci. 200: 79-84.
53. Perani, D., S. Bressi, D. Testa, et al 1995. Clinical/metabolic correlations in multiple system atrophy: a fludeoxyglucose F 18 positron emission tomographic study. Arch. Neurol. 52: 179-185.
54. Litvan, J., K.P. Bhatia, D.J. Burn, et al., Movement Disorders Society Scientific Issues Committee. 2003. Movement Disorder Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov. Disord. 18: 467-486.
55. Pirker, W., S. Asenbaum, G. Bencsits, et al 2000. [123I]beta-CIT SPECT in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration. Mov. Disord. 15: 1158-1167.
56. Foster, N.L., S. Gilman, S. Berent, et al 1988. Cerebral hypometabolism in progressive supranuclear palsy studied with positron emission tomography. Ann. Neurol. 24: 399-406.
57. Klein, R.C., B.M. de Jong, J.J. de Vries & K.L. Leenders 2005. Direct comparison between regional cerebral metabolism in progressive supranuclear palsy and Parkinson's disease. Mov. Disord. 20: 1021-1030.
58. Blin, J., J.C. Baron, P. Dubois, et al 1990. Positron emission tomography study in progressive supranuclear palsy. Arch. Neurol. 47: 747-752.
59. Mahapatra, R.K., M.J. Edwards, J.M. Schott & K.P. Bathia 2004. Corticobasal degeneration. Lancet Neurol. 3: 736-743.
60. Laureys, S., E. Salmon, G. Garraux, et al 1999. Fluorodopa uptake and glucose metabolism in early stages of corticobasal degeneration. J. Neurol. 246: 1151-1158.
61. Nagasawa, H., H. Tanji, H. Nomura, et al 1996. PET study of cerebral glucose metabolism and fluorodopa uptake in patients with corticobasal degeneration. J. Neurol. Sci. 139: 210-217.
62. Plotkin, M., H. Amthauer, S. Klaffke, et al 2005. Combined 123I-FP-CIT and 123I-IBZM SPECT for the diagnosis of parkinsonian syndromes: study on 72 patients. J. Neural. Transm. 112: 677-692.
63. Frisoni, G.B., G. Pizzolato, O. Zanetti, et al 1995. Corticobasal degeneration: neuropsychological assessment and dopamine D2 receptor SPECT analysis. Eur. Neurol. 35: 50-54.
64. Hirono, N., K. Ishii, M. Sasaki, et al 2000. Features of regional cerebral glucose metabolism abnormality in corticobasal degeneration. Dement. Geriatr. Cogn. Disord. 11: 139-146.
65. Juh, R., C.U. Pae, T.S. Kim, et al 2005. Cerebral glucose metabolism in corticobasal degeneration in comparison with progressive supranuclear palsy using statistical mapping analysis. Neurosci. Lett. 383: 22-27.
66. Rinne, J.O., D.J. Burn, C.J. Mathias, et al 1995. Positron emission tomography studies on the dopaminergic system and striatal opioid binding in the olivopontocerebellar atrophy variant of multiple system atrophy. Ann. Neurol. 37: 568-573.
67. Foster, N.L., S. Minoshima, J. Johanns, et al 2000. PET measures of benzodiazepine receptors in progressive supranuclear palsy. Neurology 54: 1768-1773.
68. Hirano, S., H. Shinotoh, H. Shimada, et al 2010. Cholinergic imaging in corticobasal syndrome, progressive supranuclear palsy and frontotemporal dementia. Brain 133: 2058-2068.
69. Duyao, M., C. Ambrose, R. Myers, et al 1993. Trinucleotide repeat length instability and age of onset in Huntington's disease. Nat. Genet. 4, 387-392.
70. Vonsattel, J.P. & M. DiFiglia 1998. Huntington disease. J. Neuropathol. Exp. Neurol. 57, 369-384.
71. Turjanski, N., R. Weeks, R. Dolan, et al 1995. Striatal D1 and D2 receptor binding in patients with Huntington's disease and other choreas. A PET study. Brain 118: 689-696.
72. Backman, L., T. Robins-Wahlin, A. Lundin, et al 1997. Cognitive deficits in Huntington's disease are predicted by dopaminergic PET markers and brain volumes. Brain 120: 2207-2217.
73. Antonini, A., K.L. Leenders & D. Eidelberg 1998. [11C]Raclopride-PET studies of the Huntington's disease rate of progression: relevance of the trinucleotide repeat length. Ann. Neurol. 43: 253-255.
74. Andrews, T.C., R.A. Weeks, N. Turjanski, et al 1999. Huntington's disease progression. PET and clinical observations. Brain 122: 2353-2363.
75. Antonini, A., K.L. Leenders, R. Spiegel, et al 1996. Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease. Brain 119: 2085-2095.
76. Kuwert, T., H. Lange, K. Langen, et al 1990. Cortical and subcortical glucose consumption measured by PET in patients with Huntington's disease. Brain 113: 1405-1423.
77. Ciarmiello, A., M. Cannella, S. Lastoria, et al 2006. Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington's disease. J. Nucl. Med. 47: 215-222.
78. Young, A.B., J.B. Penney, S. Starosta-Rubenstein, et al 1986. PET scan investigations of Huntington's disease: cerebral metabolic correlates of neurological features and functional decline. Ann. Neurol. 20: 296-303.
79. Mazziotta, J.C., M.E. Phelps, J.J. Pahl, et al 1987. Reduced cerebral glucose metabolism in asymptomatic subjects at risk for Huntington's disease. N. Engl. J. Med. 316: 357-362.
80. Feigin, A., C. Tang, Y. Ma, et al 2007. Thalamic metabolism and symptom onset in preclinical Huntington's disease. Brain 130: 2858-2867.
81. Martin, W.R., C. Clark, W. Ammann, et al 1992. Cortical glucose metabolism in Huntington's disease. Neurology 42: 223-229.
82. Feigin, A., K.L. Leenders, J.R. Moeller, et al 2001. Metabolic network abnormalities in early Huntington's disease: an [18F]FDG PET study. J. Nucl. Med. 42: 1591-1595.
83. Van Laere, K., C. Casteels, I. Dhollander, et al 2010. Widespread decrease of type 1 cannabinoid receptor availability in Huntington disease in vivo. J. Nucl. Med. 51: 1413-1417.
84. Künig, G., K.L. Leenders, R. Sanchez-Pernaute, et al 2000. Benzodiazepine receptor binding in Huntington's disease: [11C] flumazenil uptake measured using positron emission tomography. Ann. Neurol. 47: 644-648.
85. Tai, Y.F., N. Pavese, A. Gerhard, et al 2007. Imaging microglial activation in Huntington's disease. Brain Res. Bull. 72: 148-151.
86. Hurko, O. 1997. Recent advances in heritable ataxias. Ann. Neurol. 41: 4-6.
87. Paulson, H.L. & K.H. Fischbeck 1996. Trinucleotide repeats in neurogenetic disorders. Ann. Rev. Neurosci. 19: 79-107.
88. Khan, N.L., P. Giunti, M.G. Sweeney, et al 2005. Parkinsonism and nigrostriatal dysfunction are associated with spinocerebellar ataxia type 6 (SCA6). Mov. Disord. 20: 1115-1119.
89. Wüllner, U., M. Reimold, M. Abele, et al 2005. Dopamine transporter positron emission tomography in spinocerebellar ataxias type 1, 2, 3, and 6. Arch. Neurol. 62: 1280-1285.
90. Reimold, M., C. Globas, M. Gleichmann, et al 2006. Spinocerebellar ataxia type 1, 2, and 3 and restless legs syndrome: striatal dopamine D2 receptor status investigated by [11C] raclopride positron emission tomography. Mov. Disord. 21: 1667-1673.
91. Otsuka, M., Y. Ichiya, Y. Kuwabara, et al 1994. Striatal 18F-dopa uptake and brain glucose metabolism by PET in patients with syndrome of progressive ataxia. J. Neurol. Sci. 124: 198-203.
92. Wang, P.S., R.S. Liu, B.H. Yang & B.W. Soong 2007. Regional patterns of cerebral glucose metabolism in spinocerebellar ataxia type 2, 3 and 6: a voxel-based FDG-positron emission tomography analysis. J. Neurol. 254: 838-845.
93. Bressman, S.B. 2004. Dystonia genotypes, phenotypes, and classification. Adv. Neurol. 94: 101-107.
94. De La Fuente-Fernandez, R., S. Furtado, M. Guttman, et al 2003. VMAT2 binding is elevated in Dopa-responsive dystonia: visualizing empty vesicles by PET. Synapse 49: 20-28.
95. Perlmutter, J.S., M.K. Stambuk, J. Markham, et al 1997. Decreased [18F] spiperone binding in putamen in idiopathic focal dystonia. J. Neurosci. 17: 843-850.
96. Asanuma, K., Y. Ma, J. Okulski, et al 2005. Decreased striatal D2 receptor binding in non-manifesting carriers of the DYT1 dystonia mutation. Neurology 64: 347-349.
97. Carbon, M. & D. Eidelberg 2009. Abnormal structure-function relationships in hereditary dystonia. Neuroscience 164: 220-229.
98. Eidelberg, D., J.R. Moeller, A. Antonini, et al 1998. Functional brain networks in DYT1 dystonia. Ann. Neurol. 44: 303-312.
99. Carbon, M., S. Su, V. Dhawan, et al 2004. Regional metabolism in primary torsion dystonia: effects of penetrance and genotype. Neurology 62: 1384-1390.
100. Asanuma, K., Y. Ma, C. Huang, et al 2005. The metabolic pathology of dopa-responsive dystonia. Ann. Neurol. 57: 596-600.